Skip to content
Entero Healthcare Solutions logo

Entero Healthcare Solutions

ENTERO NSE
₹1,665.00 No trade today
P/E
57.77
View as Markdown
MCP
Close 4 Nov 2026 ₹1,665.00 +607.40 +57.4% 1Y
Start ₹1,057.60

Key Fundamentals

MicrocapRetailConsumer Services

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
10.50%
Debt to Equity
0.40
EPS (TTM)
₹28.82
Book Value
₹386.13
Market Cap
—
P/E (TTM)
57.77
P/B
4.31
ROE
6.94%
Dividend Yield
0.00%
EBITDA
₹285 Cr
52W High
₹1,920.00
52W Low
₹944.00
Volume
0

Peer Comparison

Consumer Discretionary › Retail › Pharmacy Retail

Entero Healthcare Solutions peer comparison
Medplus Health Services
₹600.2034.22₹7,154 Cr3.490.00%11.60%12.60%₹7,229 Cr₹211 Cr
Entero Healthcare Solutions (this company)
₹1,665.0057.77₹7,055 Cr4.310.00%6.94%10.50%₹7,128 Cr₹168 Cr
Median 2 companies₹1,132.6046.00₹7,104 Cr3.900.00%9.27%11.55%₹7,179 Cr₹190 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

55 Good

Data confidence 98/100

Category scores

Quality
30
Poor
Returns, margins, earnings quality 22% weight
Valuation
31
Poor
Cheap vs sector & own history 24% weight
Growth
91
Strong
Sales & profit trajectory 9% weight
Financial Health
46
Average
Solvency, leverage, coverage 9% weight
Momentum
86
Strong
Trend strength, vol-adjusted 12% weight
Ownership
82
Strong
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 57.3% CAGR over last 5 years
  • Company's working capital requirements have reduced from 49.4 days to 34.8 days

Weaknesses

3
  • Stock is trading at 4.37 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 6.04% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish3412
OscillatorsBullish243
Moving AveragesStrong Bullish109

Key readings

RSI (14)
56.89
Neutral
MACD (12,26,9)
−22.58
Bullish
SMA (50)
1,695.06
Bearish
SMA (200)
1,314.02
Bullish

As of

Analyst Rating

Based on 3 analysts
BUY100%

3 of 3 analysts rate Buy, 0 Hold, 0 Sell.

As of

BUY
3
100%
HOLD
0
0%
SELL
0
0%

Growth Rate

From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
5Y+30.03%
3Y+25.93%
1Y+29.34%
TTM+31.93%

Net profit

Net profit growth by window
5YTurned to profit
3YTurned to profit
1Y+36.45%
TTM+44.83%

Operating cash flow

Operating cash flow growth by window
5YTurned positive
3YTurned positive
1YTurned positive
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
5Y+3.19 pp
3Y+2.10 pp
1Y+0.66 pp
TTM+0.85 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2020₹1,350 Cr
Mar 2021₹1,773 Cr
Mar 2022₹2,522 Cr
Mar 2023₹3,300 Cr
Mar 2024₹3,922 Cr
Mar 2025₹5,096 Cr
Mar 2026₹6,591 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2020₹1.00 Cr
Mar 2021−₹15.00 Cr
Mar 2022−₹29.00 Cr
Mar 2023−₹11.00 Cr
Mar 2024₹40.00 Cr
Mar 2025₹107 Cr
Mar 2026₹146 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹107 Cr +6.6% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Generated 6 Jul 2026
AI opinion · based on fundamentals
Risk medium

Entero Healthcare Solutions is a pharmaceutical distribution company with a market cap of ~₹5,269 Cr trading at a P/E of 36.2x. The company has grown consolidated revenue from ₹2,522 Cr in FY22 to ₹6,591 Cr in FY26 (a 30% 5-year sales CAGR), while net profit rose from a loss to ₹146 Cr in FY26. However, operating margins remain thin at ~4% and return on equity is modest at around 6-7%.

Bull Case 8
  • Strong revenue growth with 5-year compounded sales CAGR of 30%, reaching ₹6,591 Cr in FY26 from ₹2,522 Cr in FY22
  • Net profit grew from a loss of ₹29 Cr in FY22 to ₹146 Cr in FY26, reflecting a 57.5% profit CAGR over 5 years
  • FY26 full-year revenue grew 31.5% YoY on a like-for-like basis, indicating continued momentum
  • Operating profit margin expanding from 0.97% in FY22 to 4.02% in FY26, showing improving operational leverage
  • Q4 FY26 net profit of ₹45 Cr showed 43.6% YoY growth, suggesting acceleration in recent quarters
  • Debt-to-equity ratio at 0.34x indicates a relatively conservative balance sheet for a distribution business
  • TTM profit growth of 26% shows earnings momentum is sustained even on a larger base
  • EBITDA grew from ₹29 Cr in FY22 to ₹285 Cr in FY26, a nearly 10x increase over four years
Bear Case 8
  • Return on equity is low at 6.07% over the last 3 years and only 7% in the latest year, weak for a company trading at 3.13x book value
  • Net profit margin remains very thin at just 2.2% in FY26 (PAT of ₹146 Cr on revenue of ₹6,591 Cr), typical of distribution but vulnerable to cost shocks
  • P/E of 36.2x is expensive relative to the modest ROE of 6-7%, implying the market is pricing in significant future improvement
  • Zero dividend payout despite reporting consecutive years of profit, offering no income return to shareholders
  • Stock has delivered -2% CAGR over 1 year, underperforming despite strong underlying profit growth
  • Interest costs rose from ₹29 Cr in FY22 to ₹54 Cr in FY26, reflecting growing working capital needs inherent to the distribution model
  • Operating in a low-margin pharmaceutical distribution business where pricing power is structurally limited
  • Trading at 3.13x book value while generating only 7% ROE means the valuation premium is not yet justified by capital efficiency

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

121d ago

TL;DR: A quiet period for Entero Healthcare with no material operational or financial news. Routine corporate governance actions like ESOP allotments and director reappointments suggest stability, while the nominee director resignation is a minor governance watch item. No clear directional catalyst is visible; the near-term outlook depends on Q1FY27 results expected in the coming weeks.

Headwinds 1
  • Nominee director resigns Jun 12

    Kevin Rohitbhai Daftary resigned as Nominee Director effective June 12, 2026, citing increased professional commitments. Loss of board representation from a nominee could signal reduced investor oversight.

Positives 1
  • ESOP allotment signals retention Jun 26

    Entero Healthcare allotted 1,475 equity shares under ESOP 2023 and reappointed two independent directors for a second term. This indicates management stability and employee retention efforts.

Neutral 1
  • Trading window closed for Q1FY27 Jun 23

    Trading window shuts from July 1, 2026, until 48 hours after Q1FY27 results are declared. This is a routine pre-results compliance measure.

Quarterly Results

₹ Cr
ENTERO quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
899
996
993
1,034
1,097
1,301
1,359
1,339
1,404
1,571
1,707
1,910
1,940
Expenses
873
968
964
1,005
1,067
1,258
1,309
1,290
1,354
1,509
1,639
1,824
1,844
Operating Profit
26
29
29
29
30
42
50
49
50
62
68
86
97
OPM %
2.9%
2.9%
2.9%
2.8%
2.8%
3.3%
3.7%
3.6%
3.6%
4%
4%
4.5%
5%
Other Income
1
2
2
9
13
11
8
7
6
5
−4
4
3
Interest
14
18
16
17
10
11
10
10
11
12
14
17
21
Depreciation
6
6
6
7
7
7
8
8
9
10
10
15
12
PBT
7
7
8
14
27
35
39
37
36
45
40
58
67
Tax %
6%
23%
16%
−56%
25%
25%
25%
16%
17%
18%
16%
22%
22%
Net Profit
6
5
7
21
21
26
29
31
30
37
34
45
52
EPS (₹)
15.18
3.19
4.22
4.82
4.62
5.43
5.85
5.9
6.39
7.26
6.35
6.44
8.77

Profit & Loss

₹ Cr
ENTERO profit and loss, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,350
1,773
2,522
3,300
3,922
5,096
6,591
7,128
Expenses
1,326
1,758
2,498
3,236
3,810
4,924
6,325
6,815
Operating Profit
23
15
24
64
112
172
266
313
OPM %
1.7%
0.8%
1%
1.9%
2.9%
3.4%
4%
4.4%
Other Income
5
11
4
6
14
39
11
8
Interest
13
20
29
49
66
42
54
64
Depreciation
12
16
20
24
25
31
43
47
PBT
4
−11
−20
−4
36
139
179
210
Tax %
67%
42%
49%
201%
−12%
23%
19%
—
Net Profit
1
−15
−29
−11
40
107
146
168
EPS (₹)
93.81
−1,551
−77.71
−28.12
8.99
21.79
26.44
28.82
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
ENTERO balance sheet, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
0.1
0.1
4
4
43
44
44
Reserves
−16
−32
−62
−73
1,595
1,681
1,645
Borrowings
603
720
974
1,101
338
385
677
Other Liabilities
162
147
210
275
369
593
1,234
Total Liabilities
749
836
1,125
1,308
2,345
2,703
3,600
Fixed Assets
186
189
262
268
289
559
958
CWIP
2
2
1
0
0
0
2
Investments
0
0
0
0
0
58
130
Other Assets
560
645
863
1,040
2,056
2,085
2,510
Total Assets
749
836
1,125
1,308
2,345
2,703
3,600

Cash Flow

₹ Cr
ENTERO cash flow, annual, ₹ crore
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−37
−69
−35
−45
−37
−77
96
Investing
−203
−31
−162
−49
−704
232
−302
Financing
217
89
211
73
863
−74
124
Net Cash Flow
−23
−11
14
−21
122
82
−82
Free Cash Flow
−81
−78
−45
−51
−41
−87
29
CFO/OP
−134
−430
−100
−51
−21
−23
56

Ratios

ENTERO financial ratios, annual
Particulars Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
63
50
54
57
57
59
67
Inventory Days
57
54
49
41
43
52
52
Days Payable
32
22
22
25
24
31
45
Cash Conversion Cycle
88
82
81
73
77
80
74
Working Capital Days
57
54
41
32
48
65
35
ROCE %
—
1%
1%
5%
7%
9%
10%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Entero Healthcare Solutions insights

62 extracted metrics across FY20–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 52.40%
  • DIIs 21.16%
  • Public 13.14%
  • Others 7.53%
  • FIIs 5.77%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Entero Healthcare Solutions

What does Entero Healthcare Solutions Ltd do?
Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services
Where is Entero Healthcare Solutions Ltd (ENTERO) listed?
Entero Healthcare Solutions Ltd trades as ENTERO on the NSE and under code 544122 on the BSE.
Which sector does Entero Healthcare Solutions Ltd belong to?
Entero Healthcare Solutions Ltd is classified under the Retail sector, in the Pharmacy Retail industry.
What is the PE ratio of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd trades at a PE ratio of 57.77 as of 4 Nov 2026, on earnings per share of ₹28.82, against a book value of ₹386.13 per share.
What is the 52-week high and low of Entero Healthcare Solutions Ltd?
Over the last 52 weeks Entero Healthcare Solutions Ltd has traded between ₹944 and ₹1,920 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Entero Healthcare Solutions Ltd?
Entero Healthcare Solutions Ltd reported a return on equity of 6.94%. Its debt-to-equity ratio is 0.40.

Company Information

Incorporated in 2018, Entero Healthcare Solutions Ltd is in the business of distribution and marketing of pharmaceutical and surgical products and allied services

Website enterohealthcare.com
CEO Mr. Prabhat Agrawal
Employees 4,111
Listed 16 Feb 2024
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/ENTERO.md for Entero Healthcare Solutions Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Retail stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month